1. Search Result
Search Result
Results for "

Glycine+transporters

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101037
    Sarcosine
    3 Publications Verification

    N-Methylglycine; Sarcosin

    Endogenous Metabolite GlyT Cancer
    Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine
  • HY-138935
    Iclepertin
    3 Publications Verification

    BI-425809

    GlyT Neurological Disease
    Iclepertin (BI-425809) is a potent, selective and orally active glycine transporter 1 (GlyT1) inhibitor. Iclepertin is inactive against GlyT2. Iclepertin can be used for Alzheimer disease and schizophrenia research .
    Iclepertin
  • HY-18638
    TCID
    Maximum Cited Publications
    6 Publications Verification

    4,5,6,7-Tetrachloroindan-1,3-dione

    Deubiquitinase Neurological Disease
    TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC50 of 0.6 μM . TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons .
    TCID
  • HY-101037S1

    N-Methylglycine-d3; Sarcosin-d3

    Isotope-Labeled Compounds Endogenous Metabolite GlyT Cancer
    Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine-d3
  • HY-109067A

    VVZ-149 hydrochloride

    GlyT 5-HT Receptor P2X Receptor Neurological Disease
    Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain .
    Opiranserin hydrochloride
  • HY-10716A

    GlyT Neurological Disease
    PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a Ki of 11.6 nM. PF-03463275 has the potential for Schizophrenia research .
    PF-03463275
  • HY-10711A

    (R)-NFPS hydrochloride

    GlyT Neurological Disease
    ALX-5407 ((R)-NFPS) hydrochloride is a selective and orally active glycine transporter GlyT1 inhibitor with an IC50 value of 3 nM. ALX-5407 hydrochloride can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .
    ALX-5407 hydrochloride
  • HY-101037R

    N-Methylglycine (Standard); Sarcosin (Standard)

    Reference Standards Endogenous Metabolite GlyT Cancer
    Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine (Standard)
  • HY-101037S

    N-Methylglycine-15N; Sarcosin-15N

    Endogenous Metabolite GlyT Cancer
    Sarcosine- 15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine-15N
  • HY-109067

    VVZ-149

    GlyT 5-HT Receptor P2X Receptor Neurological Disease
    Opiranserin (VVZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin is development as an injectable agent for the treatment of postoperative pain .
    Opiranserin
  • HY-110176

    GlyT Neurological Disease
    ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .
    ASP2535
  • HY-10711

    (R)-NFPS

    GlyT Neurological Disease
    ALX-5407 ((R)-NFPS) is a selective and orally active glycine transporter GlyT1 inhibitor with an IC50 value of 3 nM. ALX-5407 can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .
    ALX-5407
  • HY-148708

    iGluR Neurological Disease
    Oleoyl-D-lysine is a selective Glycine Transporter-2 (GlyT2) inhibitor based on lipid. Oleoyl-D-lysine reverses neuropathic pain in mice,shows antidrowsiness effect on chronic neuropathic pain. Oleoyl-D-lysine is safe and effective without respiratory depression .
    Oleoyl-D-lysine
  • HY-107526

    (Rac)-NFPS

    GlyT Neurological Disease
    NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC50s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively . NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion .
    (Rac)-ALX 5407
  • HY-W748519

    N-Methylglycine-13C3; Sarcosin-13C3

    Isotope-Labeled Compounds GlyT Endogenous Metabolite Cancer
    Sarcosine- 13C3 (N-Methylglycine- 13C3; Sarcosin- 13C3) is the 13C-labeled Sarcosine (HY-101037). Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine-13C3
  • HY-105183

    Endothelin Receptor Others
    PD 145065 is a highly potent but non-selective endothelin receptor antagonist with an IC50 value of 4 nM for the ETA receptor for rabbit renal artery vascular smooth muscle cells .
    PD 145065
  • HY-19887

    AMG747

    GlyT Neurological Disease
    Tilapertin is an oral inhibitor of glycine transporter type-1 (GlyT1).
    Tilapertin
  • HY-107527A

    GlyT Inflammation/Immunology
    Org 25543 is a selective inhibitor of the glycine transporter 2, exhibiting analgesic properties in a rat model of chronic pain.
    Org 25543
  • HY-111189

    GlyT Neurological Disease
    GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain .
    GSK931145
  • HY-113261A

    GlyT Neurological Disease
    (Rac)-Oleoylcarnitine is an endogenous acylcarnitine and a potential noncompetitive inhibitor of glycine transporter 2 (GLYT2) that can be used as a pain suppressant.
    (Rac)-Oleoylcarnitine
  • HY-10716

    GlyT Neurological Disease
    PF-03463275 hydrochloride is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a Ki of 11.6 nM. PF-03463275 hydrochloride has the potential for Schizophrenia research .
    PF-03463275 hydrochloride
  • HY-10712

    GlyT Neurological Disease
    Org-24598 is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 can inhibit the specific binding of [ 3H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM .
    Org-24598
  • HY-10713

    GlyT Neurological Disease
    Org-24598 lithium is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 lithium can inhibit the specific binding of [ 3H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM .
    Org-24598 lithium
  • HY-111162

    GPR55 GlyT Cardiovascular Disease Neurological Disease
    GSK494581A is a specific ligand for human GPR55 (pEC50 of 6.8) and also acts as an inhibitor of glycine transporter subtype 1 (GlyT1). GSK494581A may regulate pain signaling, bone morphogenesis, and vascular endothelial cell formation by binding to GPR55 .
    GSK494581A
  • HY-122666

    GlyT Metabolic Disease
    Org 25935 is a potent and selective glycine transporter 1 protein (GlyT1) inhibitor with an IC50 value of 100 nM. Org 25935 can decrease ethanol (EtOH) intake and EtOH preference in rats, whereas water intake is unaffected. Org 25935 can be used for researching alcohol dependence or abuse .
    Org 25935
  • HY-114555

    GlyT Neurological Disease
    TASP0315003 is a glycine transporter 1 (GlyT1) inhibitor. TASP0315003 potentiates NMDA receptor function by increasing synaptic glycine levels. TASP0315003 can improve cognitive dysfunction and the negative symptoms of schizophrenia without having undesirable central nervous system side effects. TASP0315003 can be used for the research of neurological disease .
    TASP0315003
  • HY-148708A

    iGluR Neurological Disease
    Oleoyl-D-lysine sodium is a selective Glycine Transporter-2 (GlyT2) inhibitor based on lipid. Oleoyl-D-lysine sodium reverses neuropathic pain in mice, shows antidrowsiness effect on chronic neuropathic pain. Oleoyl-D-lysine sodium is safe and effective without respiratory depression .
    Oleoyl-D-lysine sodium
  • HY-10716AR

    Reference Standards GlyT Neurological Disease
    PF-03463275 (Standard) is the analytical standard of PF-03463275 (HY-10716A). This product is intended for research and analytical applications. PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a Ki of 11.6 nM. PF-03463275 has the potential for Schizophrenia research .
    PF-03463275 (Standard)
  • HY-109067AR

    VVZ-149 hydrochloride (Standard)

    Reference Standards GlyT 5-HT Receptor P2X Receptor Neurological Disease
    Opiranserin hydrochloride (Standard) is the analytical standard of Opiranserin (hydrochloride) (HY-109067A). This product is intended for research and analytical applications. Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain .
    Opiranserin hydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: